Bruce Jacobs Sells 77,109 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) CFO Bruce Jacobs sold 77,109 shares of the stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $114.96, for a total transaction of $8,864,450.64. Following the transaction, the chief financial officer directly owned 244,883 shares of the company’s stock, valued at approximately $28,151,749.68. This trade represents a 23.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Kymera Therapeutics Price Performance

Shares of KYMR opened at $113.51 on Friday. The firm has a 50-day simple moving average of $87.36 and a two-hundred day simple moving average of $83.12. The stock has a market cap of $9.34 billion, a PE ratio of -31.80 and a beta of 1.95. Kymera Therapeutics, Inc. has a 1-year low of $36.65 and a 1-year high of $130.05.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Thursday, April 30th. The company reported ($0.71) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.18. The firm had revenue of $34.37 million for the quarter, compared to analyst estimates of $8.27 million. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The business’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.82) EPS. As a group, sell-side analysts expect that Kymera Therapeutics, Inc. will post -3.28 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Empowered Funds LLC purchased a new stake in Kymera Therapeutics during the 1st quarter worth approximately $203,000. Glenmede Trust Co. NA boosted its position in Kymera Therapeutics by 3.6% in the 1st quarter. Glenmede Trust Co. NA now owns 6,779 shares of the company’s stock valued at $565,000 after buying an additional 235 shares during the period. Amundi purchased a new position in Kymera Therapeutics in the 1st quarter valued at approximately $249,000. California State Teachers Retirement System grew its stake in shares of Kymera Therapeutics by 23.0% in the first quarter. California State Teachers Retirement System now owns 56,282 shares of the company’s stock worth $4,688,000 after acquiring an additional 10,540 shares in the last quarter. Finally, Eagle Health Investments LP grew its stake in shares of Kymera Therapeutics by 7.0% in the first quarter. Eagle Health Investments LP now owns 145,816 shares of the company’s stock worth $12,145,000 after acquiring an additional 9,516 shares in the last quarter.

Key Kymera Therapeutics News

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Seeking Alpha upgraded Kymera Therapeutics to Buy, citing strong pipeline progress, a roughly $1.5 billion cash position, and accelerated timing for KT-621 Phase 2b topline data by year-end 2026. The article argues the oral STAT6 degrader could compete in a large atopic dermatitis market and challenge injectable therapies. Article Title
• Positive Sentiment: Another Seeking Alpha note said Kymera is building toward a key 2H 2026 inflection point, with KT-621’s Phase 2b readout seen as a major catalyst. The commentary also highlighted rapid enrollment, a strong balance sheet, and possible partnership upside. Article Title
• Neutral Sentiment: Analysts continue to rate KYMR favorably overall, with the consensus still at Moderate Buy and recent target increases from firms including Truist and Canaccord Genuity suggesting confidence in the company’s pipeline and long-term prospects.
• Negative Sentiment: Recent insider sales from CEO Nello Mainolfi, CFO Bruce N. Jacobs, and insider Noah Goodman may weigh on sentiment, as the transactions were sizable and follow additional selling earlier in the quarter. Article Title

Wall Street Analysts Forecast Growth

A number of research analysts have commented on KYMR shares. BTIG Research restated a “buy” rating and set a $134.00 price target on shares of Kymera Therapeutics in a research note on Thursday, June 25th. B. Riley Financial lifted their price objective on Kymera Therapeutics from $117.00 to $155.00 and gave the company a “buy” rating in a research note on Monday. Bank of America lifted their price objective on Kymera Therapeutics from $110.00 to $125.00 and gave the company a “buy” rating in a research note on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kymera Therapeutics in a report on Tuesday, April 21st. Finally, Loop Capital set a $97.00 target price on Kymera Therapeutics in a research note on Monday, June 8th. One analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $121.41.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.